1. Day S, Acquah K, Lee PP, Mruthyunjaya P, Sloan FA. Medicare costs for neovascular age-related macular degeneration, 1994-2007. Am J Ophthalmol. 2011; 152(6): 1014-1020. doi: 10.1016/j.ajo.2011.05.008
2. Qualls LG, Hammill BG, Wang F, et al. Costs of newly diagnosed neovascular age-related macular degeneration among medicare beneficiaries, 2004-2008. Retina. 2013; 33(4): 854-861. doi: 10.1097/IAE.0b013e31826f065e
3. Haller JA. Current anti-vascular endothelial growth factor dosing regimens: benefits and burden. Ophthalmology. 2013; 120(5 Suppl): S3-S7. doi: 10.1016/j.ophtha.2013.01.057
4. Jonas JB. Global prevalence of age-related macular degeneration. Lancet Glob Health. 2014; 2(2): e65-e66. doi: 10.1016/S2214-109X(13)70163-3
5. Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014; 2(2): e106-e116. doi: 10.1016/S2214-109X(13)70145-1
6. Chew EY, Clemons TE, Bressler SB, et al. AREDS2-HOME Study Research Group. Randomized trial of a home monitoring system for early detection of choroidal neovascularization home monitoring of the Eye (HOME) study. Ophthalmology. 2014; 121(2): 535-544. doi: 10.1016/j.ophtha.2013.10.027
7. Faes L, Bodmer NS, Bachmann LM, Thiel MA, Schmid MK. Diagnostic accuracy of the Amsler grid and the preferential hyperacuity perimetry in the screening of patients with age-related macular degeneration: systematic review and meta-analysis. Eye (Lond). 2014; 28(7): 788-796. doi: 10.1038/eye.2014.104
8. Han DP. The ForeSeeHome device and the HOME study: a milestone in the self-detection of neovascular age-related macular degeneration. JAMA Ophthalmol. 2014; 132(10): 1167-1168. doi: 10.1001/jamaophthalmol.2014.1405
9. Westheimer G. Editorial: Visual acuity and hyperacuity. Invest Ophthalmol. 1975; 14(8): 570-572.
10. Alster Y, Bressler NM, Bressler SB, et al. Preferential Hyperacuity Perimetry Research Group. Preferential Hyperacuity Perimeter (PreView PHP) for detecting choroidal neovascularization study. Ophthalmology. 2005; 112(10): 1758-1765. doi: 10.1016/j. ophtha.2005.06.008
11. Bourne RR, Stevens GA, White RA, et al. Vision Loss Expert Group. Causes of vision loss worldwide, 1990-2010: a systematic analysis. Lancet Glob Health. 2013; 1(6): e339-e349. doi: 10.1016/S2214-109X(13)70113-X
12. Ferris FL 3rd, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol. 1984; 102(11): 1640-1642. doi: 10.1001/archopht.1984.01040031330019
13. Klein R, Peto T, Bird A, Vannewkirk MR. The epidemiology of age-related macular degeneration. Am J Ophthalmol. 2004; 137(3): 486-495. doi: 10.1016/j.ajo.2003.11.069
14. Bressler NM, Doan QV, Varma R, et al. Estimated cases of legal blindness and visual impairment avoided using ranibizumab for choroidal neovascularization: non-hispanic white population in the United States with age-related macular degeneration. Arch Ophthalmol. 2011; 129(6): 709-717. doi: 10.1001/archophthalmol.2011.140
15. Bloch SB, Larsen M, Munch IC. Incidence of legal blindness from age-related macular degeneration in Denmark: year 2000 to 2010. Am J Ophthalmol. 2012; 153(2): 209-213. doi: 10.1016/j.ajo.2011.10.016
16. Keenan TD, Kelly SP, Sallam A, Mohamed Q, Tufail A, Johnston RL. Incidence and baseline clinical characteristics of treated neovascular age-related macular degeneration in a well-defined region of the UK. Br J Ophthalmol. 2013; 97(9): 1168-1172. doi: 10.1136/bjophthalmol-2013-303233
17. Finger RP, Wiedemann P, Blumhagen F, Pohl K, Holz FG. Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study: a non-interventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany. Acta Ophthalmol. 2013; 91(6): 540-546. doi: 10.1111/j.1755-3768.2012.02493.x
18. Rakic JM, Leys A, Brié H, et al. Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: the HELIOS study. Clin Ophthalmol. 2013; 7: 1849-1858. doi: 10.2147/OPTH.S49385
19. Finger RP, Guymer RH, Gillies MC, Keeffe JE. The impact of anti-vascular endothelial growth factor treatment on quality of life in neovascular age-related macular degeneration. Ophthalmology. 2014; 121(6): 1246-1251. doi: 10.1016/j.ophtha.2013.12.032
20. Han DP. Age-related macular degeneration, anti-VEGF therapy, and ophthalmic imaging: is there a best practice? JAMA Ophthalmol. 2013; 131(9): 1124-1126. doi: 10.1001/jamaophthalmol.2013.432
21. Tschuor P, Pilly B, Venugopal D, Gale RP. Optimising assessment intervals improves visual outcomes in ranibizumab-treated age-related neovascular degeneration: using the stability phase as a benchmark. Graefes Arch Clin Exp Ophthalmol. 2013; 251(10): 2327-2330. doi: 10.1007/s00417-013-2332-5
22. Das R, Shi Y, Silvestri G, Chakravarthy U. Distortion maps from preferential hyperacuity perimetry are helpful in monitoring functional response to Lucentis therapy. Retina. 2009; 29(7): 1013-1018. doi: 10.1097/IAE.0b013e3181a91dbf
23. Querques G, Berboucha E, Leveziel N, Pece A, Souied EH. Preferential hyperacuity perimeter in assessing responsiveness to ranibizumab therapy for exudative age-related macular degeneration. Br J Ophthalmol. 2011; 95(7): 986-991. doi: 10.1136/bjo.2010.190942
24. Querques G, Querques L, Rafaeli O, Canoui-Poitrine F, Bandello F, Souied EH. Preferential hyperacuity perimeter as a functional tool for monitoring exudative age-related macular degeneration in patients treated by intravitreal ranibizumab. Invest Ophthalmol Vis Sci. 2011; 52(9): 7012-7018. doi: 10.1167/iovs.11-7517